Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study

Open access

Abstract

BACKGROUND: Semaglutide is highly effective for decreasing weight. Concomitant loss of muscle mass often accompanies weight loss and may have consequences on muscle function. METHODS: This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD). Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4). Psoas volume and fat fraction were assessed from liver magnetic resonance imaging, and physical function was assessed by 10-time chair rise test and 4 m gait speed. Mean change from baseline to week 24 was estimated with linear regression modeling. RESULTS: Fifty-one PWH were enrolled (muscle measures n = 46). The mean age was 50 years (standard deviation, 11), body mass index was 35.5 kg/m2 (5.6), 43% were women, 33% Black, and 39% Hispanic/Latino. Psoas muscle volume decreased by 9.3% (95% confidence interval [CI]: -13.4 to -5.2; P < .001) over 24 weeks, but psoas muscle fat did not significantly change (-0.42%; 95% CI: -1.00 to .17; P = .16). Chair rise and gait speed showed nonsignificant improvements of 1.27 seconds (95% CI: -2.7 to .10) and 0.05 m/sec (95% CI: -.01 to .10), respectively (both P > .07). The prevalence of slow gait speed (<1 m/sec) decreased from 63% to 46% (P = .029). CONCLUSIONS: In PWH receiving semaglutide for MASLD, despite decreased psoas muscle volume, there was no significant change in physical function, suggesting function was maintained despite significant loss of muscle. CLINICAL TRIALS REGISTRATION: NCT04216589.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciae384

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Eckard, 2024, Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial, Lancet Diabetes Endocrinol, S2213–8587, 00150-5

Cited by

See all 44

Metadata

Authors
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., Avihingsanon, A., Sattler, F. R., & Erlandson, K. M.
Affiliations
  • University of Colorado Anschutz (US)
  • The University of Texas Health Science Center at Houston (US)
  • Harvard University (US)
  • Texas A&M University (US)
  • National Institute of Allergy and Infectious Diseases (Contractor) , Rockville, Maryland ,
  • Johns Hopkins University (US)
  • The University of Texas Medical Branch at Galveston (US)
  • Thai Red Cross Society (TH)
  • University of Southern California (US)
Corresponding author
  • Ditzenberger, Grace L
  • Erlandson, Kristine M
Venue
Clinical Infectious Diseases
Published
2024-07-24
Volume
80
Issue
2
Pages
389-396
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W4400967991
Cited by
44
References
40
Citations by year
2026: 24 · 2025: 15 · 2024: 5
FWCI
23.82
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • NIAID (UM1 AI068634, UM1 AI068636, UM1 AI106701)
  • NIH
  • McGovern School of Medicine at UTHealth (T32 AI150547, K24 AI120834)
  • National Institute on Aging (K24 AG082527)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
semaglutide, HIV, non-alcoholic fatty liver disease, muscle mass loss, muscle fat fraction, physical function, walking speed, chair stand test, weight loss, GLP-1 receptor agonists
MeSH terms
Semaglutide, Adult, Glucagon-Like Peptides, Fatty Liver, Female, Humans, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Weight Loss, HIV Infections, Psoas Muscles, Muscle, Skeletal, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. https://app.cochat.ai/papers/10.1093/cid/ciae384
The paper
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., Avihingsanon, A., Sattler, F. R., & Erlandson, K. M. (2025). Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae384

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.